Delaying the Hormone Refractory Prostate Cancer by a Dietary Triterpene Lupeol
通过膳食三萜羽扇豆醇延缓激素难治性前列腺癌的发生
基本信息
- 批准号:7661136
- 负责人:
- 金额:$ 16.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-07 至 2010-01-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAdjuvantAndrogen AntagonistsAndrogen ReceptorAndrogensAnimal ModelAntiandrogen TherapyApoptoticB-LymphocytesCancer EtiologyCancer PatientCarcinomaCause of DeathCellsCessation of lifeCharacteristicsChemopreventionChoristomaClinicalDataDevelopmentDiseaseDistantERBB2 geneElderberryEventExhibitsFigs - dietaryFoundationsFruitFutureGelatinase AGenesGoalsGrapesGrowthHormonesHumanIn VitroInvadedLeadLegal patentLigandsMalignant neoplasm of prostateMango - dietaryMediatingMedicinal PlantsMetastatic Prostate CancerMolecularMusNatureNutrientOlives - dietaryOperative Surgical ProceduresPathway interactionsPatientsPhenotypeProcessProstate carcinomaProstatic NeoplasmsPublishingQuality of lifeReceptor SignalingRecurrenceRefractoryRefractory DiseaseResistanceSignal PathwaySignal TransductionSiteSomatotropinStagingStrawberriesTestingTherapeuticTherapeutic AgentsTransgenic MiceTriterpenesTumorigenicityVegetable OilsXenograft procedurebasebonecancer cellcancer therapychemotherapeutic agentfruits and vegetableshormone refractory prostate cancerhormone sensitivitylupeollymph nodesmenmouse modelnovelnovel strategiesnovel therapeuticspre-clinicalpreventpublic health relevancereceptortherapeutic targettreatment strategytumor
项目摘要
DESCRIPTION (provided by applicant): Persistence of cancer cells even after surgery and androgen-ablation therapy, their proliferation, androgen- independence and invasion to distant sites is the major cause of deaths in human prostate cancer patients. Delaying or slowing down the process of prostate cancer cells to become highly aggressive hormone refractory phenotype would lead to the prolongation in the survival, better management and in improvement in the quality of life of prostate cancer patients. Unfortunately, patients with advanced hormone refractory tumors most often fail to respond to or very poorly respond to current conventional cancer therapies. The challenges in the implementation of effective therapeutic strategies for the treatment of advanced hormone refractory prostate cancer reflect the multidimensional nature and functional significance of pro-survival and pro-proliferation signaling pathways in the emergence of therapeutic resistance of prostate tumors. The persistent activation of androgen receptor in hormone refractory prostate cancer cells even under non-androgen conditions has been associated with the activation of PI3K/Akt signaling. The activated PI3K/Akt forms a signaling axis with 2- catenin and NF:B pathways, thus converging on common downstream targets, and ultimately leads to the hormone-refractory, chemoresistant and highly aggressive prostate cancer cells with an ability to migrate and invade heterotopic tissues such as bones and lymph nodes in humans. While a full understanding of the hormone-refractory and pro-survival characteristics of multiple signaling pathways is still evolving, the impact that Akt/ss-catenin/NF:B signaling axis has been widely accepted and there are efforts to utilize these pathways for therapeutic targeting of its key signaling steps. Thus, there is a strong unmet need to develop new therapeutic agents (with an ability to target multiple molecular pathways) which are effective against androgen-independent prostate tumor development as well as the recurrence of disease. We will provide compelling evidence that Lupeol, (a non-nutrient and non-toxic natural agent present in olive, strawberry, grapes, mango, figs and vegetable oils) could be an ideal multi-target agent which could prevent or delay the onset of transition of hormone-dependent to hormone-independent process in human prostate cancer. We hypothesize that Lupeol will prevent /or delay the transformation of hormone-dependent CaP to hormone independent disease through the disruption of Akt/2-catenin/NF:B signaling axis. To achieve our goal, we propose two specific aims. Under the first specific aim, we propose to investigate whether Lupeol (i) prevents or delays the onset of androgen-independence in human CaP cells and (ii) sensitizes the hormone refractory CaP cells for androgen-antagonist treatment under in vitro conditions. Under the second specific aim, we propose to investigate whether Lupeol (iii) alone and in combination with androgen ablation prevents or delays the onset of emergence of androgen-independence of human CaP tumors and (iv) sensitizes the hormone refractory CaP tumors for androgen-antagonist therapy, in an orthotopic xenograft mouse model. We believe that this proposal will be extremely valuable in providing a novel fruit and vegetable based agent for chemoprevention and possibly for treating early as well as advanced prostate cancer. PUBLIC HEALTH RELEVANCE: We believe that this proposal will be extremely valuable in providing a novel fruit and vegetable based agent with a known mechanism of action for delaying or preventing the onset of transition of hormone-dependent prostate cancer to hormone refractory and chemoresistant phenotype. Successful completion of this proposal will establish the potential of Lupeol for the treatment of advanced prostate cancer.
描述(由申请人提供):即使在手术和雄激素消融治疗后,癌细胞的持续存在,它们的增殖,雄激素不依赖性和向远处的侵袭是人类前列腺癌患者死亡的主要原因。延缓或减缓前列腺癌细胞向高侵袭性激素难治性表型转变的过程,可以延长前列腺癌患者的生存期,改善治疗,提高患者的生活质量。不幸的是,晚期激素难治性肿瘤的患者通常对目前的常规癌症治疗没有反应或反应很差。对晚期激素难治性前列腺癌实施有效治疗策略所面临的挑战,反映了促生存和促增殖信号通路在前列腺肿瘤治疗耐药出现中的多维性和功能意义。即使在非雄激素条件下,激素难治性前列腺癌细胞中雄激素受体的持续激活与PI3K/Akt信号的激活有关。活化的PI3K/Akt与2- catenin和NF:B通路形成信号轴,汇聚到共同的下游靶点,最终导致具有激素难耐、化疗耐药和高侵袭性的前列腺癌细胞,具有迁移和侵袭人类骨骼、淋巴结等异位组织的能力。虽然对多种信号通路的激素耐受性和促生存特性的充分理解仍在不断发展,但Akt/ss-catenin/NF:B信号轴的影响已被广泛接受,并且正在努力利用这些信号通路来治疗其关键信号步骤。因此,迫切需要开发新的治疗药物(具有靶向多种分子途径的能力),以有效对抗雄激素非依赖型前列腺肿瘤的发展以及疾病的复发。我们将提供令人信服的证据,证明Lupeol(一种存在于橄榄、草莓、葡萄、芒果、无花果和植物油中的无营养无毒的天然制剂)可能是一种理想的多靶点制剂,可以预防或延缓人类前列腺癌中激素依赖性向激素非依赖性转变的发生。我们假设Lupeol可以通过破坏Akt/2-catenin/NF:B信号轴来阻止/或延缓激素依赖性CaP向激素非依赖性疾病的转变。为实现这一目标,我们提出了两个具体目标。在第一个特定目的下,我们建议研究Lupeol是否(i)阻止或延迟人类CaP细胞雄激素依赖性的发生,以及(ii)在体外条件下使激素难治性CaP细胞敏化以接受雄激素拮抗剂治疗。在第二个特定目的下,我们建议在一个原位异种移植小鼠模型中研究Lupeol (iii)单独使用和联合雄激素消融是否可以预防或延迟人类CaP肿瘤雄激素依赖性的出现,以及(iv)使激素难治性CaP肿瘤对雄激素拮抗剂治疗增敏。我们相信,这一建议将为化学预防提供一种新的基于水果和蔬菜的药物,并可能用于治疗早期和晚期前列腺癌。公共卫生相关性:我们相信这一建议将非常有价值,因为它提供了一种新的基于水果和蔬菜的药物,具有已知的作用机制,可以延缓或预防激素依赖性前列腺癌向激素难治性和化疗耐药表型的转变。该提案的成功完成将确立Lupeol治疗晚期前列腺癌的潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mohammad Saleem Bhat其他文献
Mohammad Saleem Bhat的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mohammad Saleem Bhat', 18)}}的其他基金
Novel targeted chemo/immunotherapy approach for localized and metastatic CaP
针对局部和转移性 CaP 的新型靶向化疗/免疫治疗方法
- 批准号:
10415649 - 财政年份:2021
- 资助金额:
$ 16.33万 - 项目类别:
Novel gene that determines metastatic phenotype in African-American men with PCa
决定非裔美国前列腺癌男性转移表型的新基因
- 批准号:
9103022 - 财政年份:2015
- 资助金额:
$ 16.33万 - 项目类别:
Delaying the Hormone Refractory Prostate Cancer by a Dietary Triterpene Lupeol
通过膳食三萜羽扇豆醇延缓激素难治性前列腺癌的发生
- 批准号:
7835621 - 财政年份:2009
- 资助金额:
$ 16.33万 - 项目类别:
Lupeol, A Novel Fuit and Vegetable Based Triterpene for Prostate Cancer
羽扇豆醇,一种治疗前列腺癌的新型水果和植物三萜
- 批准号:
7321036 - 财政年份:2007
- 资助金额:
$ 16.33万 - 项目类别:
Lupeol, A Novel Fuit and Vegetable Based Triterpene for Prostate Cancer
羽扇豆醇,一种治疗前列腺癌的新型水果和植物三萜
- 批准号:
7472599 - 财政年份:2007
- 资助金额:
$ 16.33万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 16.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 16.33万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 16.33万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 16.33万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 16.33万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 16.33万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 16.33万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 16.33万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 16.33万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 16.33万 - 项目类别:














{{item.name}}会员




